RU2018128737A - Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов - Google Patents
Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов Download PDFInfo
- Publication number
- RU2018128737A RU2018128737A RU2018128737A RU2018128737A RU2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A
- Authority
- RU
- Russia
- Prior art keywords
- imatinib
- acceptable salt
- prevention
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Claims (5)
1. Применение иматиниба (4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-((4-пиридин-3-ил)пиримидин-2-ил-амино)фенил]-бензамид) или его фармацевтически приемлемой соли в качестве агента для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов.
2. Применение по п.1 в качестве приемлемой соли иматиниба иматиниб мезилата.
3. Применение иматиниба или его фармацевтически приемлемой соли по пп.1 и 2 для лечения или предупреждений заболевания, связанного с проницаемостью сосудов, выбранного из группы, состоящей из хороидальной неоваскуляризации, пигментного ретинита, связанного с глаукомой, ретролентальной фиброплазии (синдрома Терри), диабетического макулярного отёка, возрастной дегенерации жёлтого пятна, глаукомы, дистрофии роговицы, отслоения сетчатки, Штаргардта дегенерации жёлтого пятна, аутосомных доминантных старческих бляшек, диабетической ретинопатии, дистрофии жёлтого пятна (болезни Беста), цистоидного отёка жёлтого пятна, ишемической ретинопатии, дегенеративного заболевания сетчатки, вызванного воспалением, юношеского, связанного с Х-хромосомой ретиношизиса, Malattia Leventinese (ML), сотовидного хориоидита Дойна, и воспалительных заболеваний, связанных с клетками эндотелия сосудов.
4. Применение иматиниба или его фармацевтически приемлемой соли по пп.1 и 2 в дозе от 1 до 20 мг/кг в сутки для лечения или предупреждения диабетической ретинопатии.
5. Применение иматиниба или его фармацевтически приемлемой соли по пп.1 и/или 4 в количестве 0,001 - 50 вес.% для приготовления фармацевтической композиции в пересчёте на ее общий вес.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0065193 | 2012-06-18 | ||
KR1020120065193A KR101386697B1 (ko) | 2012-06-18 | 2012-06-18 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014151382A Division RU2014151382A (ru) | 2012-06-18 | 2013-06-10 | Композиция для лечения или профилактики заболеваний, вызванных расстройствами сосудистой проницаемости, содержащая иматиниб или его фармацевтически приемлемые соли в качестве активного ингредиента |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2018128737A true RU2018128737A (ru) | 2019-03-14 |
RU2018128737A3 RU2018128737A3 (ru) | 2019-03-14 |
Family
ID=49768959
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018128737A RU2018128737A (ru) | 2012-06-18 | 2013-06-10 | Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов |
RU2014151382A RU2014151382A (ru) | 2012-06-18 | 2013-06-10 | Композиция для лечения или профилактики заболеваний, вызванных расстройствами сосудистой проницаемости, содержащая иматиниб или его фармацевтически приемлемые соли в качестве активного ингредиента |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014151382A RU2014151382A (ru) | 2012-06-18 | 2013-06-10 | Композиция для лечения или профилактики заболеваний, вызванных расстройствами сосудистой проницаемости, содержащая иматиниб или его фармацевтически приемлемые соли в качестве активного ингредиента |
Country Status (11)
Country | Link |
---|---|
US (1) | US9511068B2 (ru) |
EP (1) | EP2862573B1 (ru) |
JP (1) | JP6030234B2 (ru) |
KR (1) | KR101386697B1 (ru) |
CN (2) | CN107496426A (ru) |
BR (1) | BR112014032264A8 (ru) |
CA (1) | CA2876926C (ru) |
ES (1) | ES2668908T3 (ru) |
MX (1) | MX365021B (ru) |
RU (2) | RU2018128737A (ru) |
WO (1) | WO2013191401A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101498973B1 (ko) | 2013-11-21 | 2015-03-05 | 현대모비스(주) | 차량용 주차 지원 시스템 및 방법 |
GB201401005D0 (en) * | 2014-01-21 | 2014-03-05 | Ucl Business Plc | Inhibitor |
KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB0201882D0 (en) | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
CA2480809A1 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
NZ580384A (en) * | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
EP2281885A1 (en) * | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
GB0421438D0 (en) * | 2004-09-27 | 2004-10-27 | Astrazeneca Ab | Combination therapy |
BRPI0511805A (pt) | 2004-06-04 | 2008-01-15 | Bioniche Life Sciences Inc | uso de imatinib para tratar distúrbios hepáticos e infecções virais |
AU2005288737B2 (en) | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Combination comprising ZD6474 and imatinib |
AU2005288736B2 (en) | 2004-09-27 | 2008-08-14 | Astrazeneca Ab | Cancer combination therapy comprising AZD2171 and imatinib |
WO2006041976A1 (en) * | 2004-10-08 | 2006-04-20 | Novartis Ag | Combination of organic compounds |
KR101276425B1 (ko) | 2005-06-03 | 2013-06-19 | 노파르티스 아게 | 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 |
US20080003219A1 (en) | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
EP1920767A1 (en) | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
MX2009004861A (es) | 2006-11-09 | 2009-05-21 | Abbott Gmbh & Co Kg | Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa. |
PT2305263E (pt) | 2007-06-07 | 2012-10-22 | Novartis Ag | Formas amorfas estabilizadas de mesilato de imatinib |
TW201102068A (en) | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
KR101138840B1 (ko) * | 2009-12-28 | 2012-05-10 | 주식회사 셀트리온화학연구소 | 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 |
-
2012
- 2012-06-18 KR KR1020120065193A patent/KR101386697B1/ko active IP Right Grant
-
2013
- 2013-06-10 US US14/409,441 patent/US9511068B2/en active Active
- 2013-06-10 WO PCT/KR2013/005068 patent/WO2013191401A1/ko active Application Filing
- 2013-06-10 RU RU2018128737A patent/RU2018128737A/ru unknown
- 2013-06-10 EP EP13807815.9A patent/EP2862573B1/en active Active
- 2013-06-10 CN CN201710777309.5A patent/CN107496426A/zh active Pending
- 2013-06-10 CN CN201380032289.9A patent/CN104582704A/zh active Pending
- 2013-06-10 JP JP2015518325A patent/JP6030234B2/ja active Active
- 2013-06-10 MX MX2014015785A patent/MX365021B/es active IP Right Grant
- 2013-06-10 ES ES13807815.9T patent/ES2668908T3/es active Active
- 2013-06-10 CA CA2876926A patent/CA2876926C/en active Active
- 2013-06-10 BR BR112014032264A patent/BR112014032264A8/pt not_active Application Discontinuation
- 2013-06-10 RU RU2014151382A patent/RU2014151382A/ru unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014032264A8 (pt) | 2022-03-03 |
US20150320750A1 (en) | 2015-11-12 |
MX2014015785A (es) | 2015-06-10 |
EP2862573A4 (en) | 2016-01-27 |
BR112014032264A2 (pt) | 2017-06-27 |
CA2876926C (en) | 2017-04-04 |
KR20130141998A (ko) | 2013-12-27 |
CN104582704A (zh) | 2015-04-29 |
EP2862573A1 (en) | 2015-04-22 |
MX365021B (es) | 2019-05-20 |
KR101386697B1 (ko) | 2014-04-18 |
JP2015520226A (ja) | 2015-07-16 |
JP6030234B2 (ja) | 2016-11-24 |
RU2018128737A3 (ru) | 2019-03-14 |
CN107496426A (zh) | 2017-12-22 |
CA2876926A1 (en) | 2013-12-27 |
US9511068B2 (en) | 2016-12-06 |
EP2862573B1 (en) | 2018-03-07 |
RU2014151382A (ru) | 2016-08-10 |
ES2668908T3 (es) | 2018-05-23 |
WO2013191401A1 (ko) | 2013-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014078778A3 (en) | Antiviral azasugar-containing nucleosides | |
JP2014527407A5 (ru) | ||
JP2007519649A5 (ru) | ||
JP2015025011A5 (ru) | ||
JP2016515561A5 (ru) | ||
JP2009532464A5 (ru) | ||
RU2016121150A (ru) | Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума | |
WO2009080836A3 (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
IL189032A (en) | Small compounds that correct incorrect folding of protein and their use | |
JP2016535795A5 (ru) | ||
JP2013529210A5 (ru) | ||
GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
JP2010526840A5 (ru) | ||
JP2016027060A5 (ru) | ||
JP2016505637A5 (ru) | ||
JP2009542581A5 (ru) | ||
IL234262A (en) | Pharmaceuticals containing ccr3 inhibitors | |
WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
JP2016020375A5 (ru) | ||
RU2018128737A (ru) | Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
JP2013534527A5 (ru) | ||
JP2008516959A5 (ru) | ||
JP2013528563A5 (ru) | ||
JP2012528824A5 (ru) |